COVID-19 research at MORU
Summary of the COVID research at MORU
COPCOV trial
COPCOV is a global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV ended recruitment in December 2021 with 4,646 participants enrolled from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Niger, Pakistan, Thailand, the UK and Zambia. Preliminary study results are expected within Q2 2022.
SEBCOV study
SEBCOV aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, travel restrictions and other for the COVID-19 pandemic.